REFERENCES
- Dignani MC, Anaissie EJ. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl 1): 67–75.
- Nucci M, Marr KA, Queiros-Tellez F et al. Fusarium infection in hematopoietic stem cell tansplant recipients. Clin Infect Dis 2004; 38: 1237–42
- Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother 2003; 15, Suppl.2: 28-35.
- Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infection in haematological malignancy and solid organ trasplantation. Eur J Clin Microbiol Infect Dis 1997; 16: 424–36.
- Boutati El, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with haematological malignancy: ten years' experience at a cancer centre and implications for management. Blood 1997; 99: 999–1008.
- Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1999; 28: 7–15.
- Sampathkumar P, Paya, CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32: 1237–40.
- Lodato F, Tame MR, Montagnani M, et al. Systemic fungemia and hepatic localization of Fusarium solani in liver transplant patient: an emerging fungal agent. Liver Transplant 2006; 12: 1711–4.
- McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36: 239–42.
- Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal sus-ceptibility of clinical and environmental Fusarium spp strains. J Antimicrob Chemother 1997; 39: 239–42.
- Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treat-ment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36: 1122–1131.
- Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusar-iosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005; 40: 1212–1213.
- Raad 11, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underly-ing hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398–1403.
- Pfaller MA, Marco F, Messre SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991, against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251–5.
- Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patients with acute leukaemia treated with caspofungin. Clin Infect Dis 2003; 36: 1349–1350.
- Garbino J, Uckay I, Rohner P, Lew D, Van Delden C. Fusarium peritonitis concomitant to kidney transplantation suc-cessfully managed with voriconazole: case report and review of the literature. Transplant Int 2005; 18: 613–8.